Mariam Medical Inc. is an emerging biotechnology company focused on bringing cancer and broad spectrum antiviral therapeutics (BSAV) to market:
Mariam Medical is developing RNAi (“gene silencing”) based therapeutics against genetically-defined targets in multiple cancer areas, including liver, breast, prostate, NSCLC, ovarian, thyroid, melanoma, and neuro and glioblastoma cancers.
We have successfully killed human breast cancer cells in vitro using gene silencing techniques, indicating potential blockbuster therapies for breast and prostate cancer (over $17 billion in addressable markets).
Mariam Medical holds global exclusive rights on the patent for silencing this gene target.
Mariam Medical has identified and has exclusive global rights to broad spectrum antiviral small molecule compounds that can block SARS-CoV (SARS), EBOV (Ebola), HeV (Hendra), and NiV (Nipah) viral infections.